H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $5.00 price target, citing Phase 3 trial concerns and no change in approval probability. SRPT's stock is down 20% YTD but has a Fair Value of $21.05. Q2 2026 earnings beat expectations, but sales declined due to reduced demand for ELEVIDYS. Analysts have mixed opinions, with Jefferies and Mizuho maintaining Buy/Outperform ratings and higher targets.
How this was made
The 30-second read
Why it matters
The downgrade and $5 target represent new analyst sentiment that could drive short-term price declines.
Market read
Analyst downgrade may prompt sell-offs in SRPT and influence sentiment in the biotech sector.
What to watch
Potential pipeline progress and upcoming trial data could offset short-term rating pressure.
Background
The article combines an analyst rating reiteration with a brief recap of recent earnings results.
Ticker impact
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics with a $5 price target despite recent earnings beat.
likely downward pressure as the market prices in the sell rating and $5 target.
The rating change is a fresh analyst opinion that could influence short-term trading decisions.
Market effects
May weigh on other biotech stocks as analysts reassess valuation multiples.
Limited to US biotech sector.
Low
Counterpoint
Some investors may view the sell rating as overly pessimistic given the earnings beat.
Key entities
- CompanySarepta Therapeutics
Biotech firm developing Duchenne muscular dystrophy therapies.
- AnalystH.C. Wainwright
Equity research firm covering biotech.
